DermaBio
DermaBio delivers AI-based precision medicine via skin biomarkers and predictive modeling.
Company Overview
Snapshot
Founded in July 2022 by Miriam Oron Ph.D. and Meital Portugal, DermaBio operates with 1–10 employees. The company has completed 2 funding rounds, attracting 1 investor.
Business overview
DermaBio is a Health Tech & Life Sciences company focused on precision medicine. The company develops an AI-powered platform that combines skin biomarker analysis, a proprietary clinical assay, and advanced data modeling to predict patient response to biologic therapies. This technology aims to optimize treatment outcomes and reduce healthcare costs by providing actionable data to clinicians and payers. DermaBio serves the healthcare industry, specifically targeting laboratories, providers, and insurance companies in North America and Europe.
Log in to access full profile ›Company Intelligence Q&A
- What is DermaBio's primary focus in healthcare?
- DermaBio focuses on AI-based precision medicine, utilizing skin biomarkers and predictive modeling to anticipate patient responses to biologic therapies, aiming to improve treatment efficacy and reduce healthcare costs.
- When was DermaBio founded and by whom?
- DermaBio was founded in July 2022 by co-founders Miriam Oron Ph.D. (CEO) and Meital Portugal (CTO).
- What is DermaBio's most recent funding activity?
- This round was one of two funding rounds the company has completed to date.
- What markets does DermaBio currently target?
- DermaBio targets the North American and European markets with its precision medicine platform.